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Abstract
Background/Objectives: Endocannabinoids (ECs) are associated with obesity and ectopic fat accumulation, both of
which play a role in the development of cardiovascular disease (CVD) in type 2 diabetes (T2D). The effect of prolonged
caloric restriction on ECs in relation to fat distribution and cardiac function is still unknown. Therefore, our aim was to
investigate this relationship in obese T2D patients with coronary artery disease (CAD).
Subjects/Methods: In a prospective intervention study, obese T2D patients with CAD (n = 27) followed a 16 week
very low calorie diet (VLCD; 450–1000 kcal/day). Cardiac function and fat accumulation were assessed with MRI and
spectroscopy. Plasma levels of lipid species, including ECs, were measured using liquid chromatography-mass
spectrometry.
Results: VLCD decreased plasma levels of virtually all measured lipid species of the class of N-acylethanolamines
including the EC anandamide (AEA; −15%, p = 0.016), without decreasing monoacylglycerols including the EC 2-
arachidonoylglycerol (2-AG). Baseline plasma AEA levels strongly correlated with the volume of subcutaneous white
adipose tissue (SAT; R2 = 0.44, p < 0.001). VLCD decreased the volume of SAT (−53%, p < 0.001), visceral white adipose
tissue (VAT) (−52%, p < 0.001), epicardial white adipose tissue (−15%, p < 0.001) and paracardial white adipose tissue
(−28%, p < 0.001). VLCD also decreased hepatic (−86%, p < 0.001) and myocardial (−33%, p < 0.001) fat content. These
effects were accompanied by an increased left ventricular ejection fraction (54.8 ± 8.7–56.2 ± 7.9%, p = 0.016).
Conclusions: Caloric restriction in T2D patients with CAD decreases AEA levels, but not 2-AG levels, which is paralleled
by decreased lipid accumulation in adipose tissue, liver and heart, and improved cardiovascular function. Interestingly,
baseline AEA levels strongly correlated with SAT volume. We anticipate that dietary interventions are worthwhile
strategies in advanced T2D, and that reduction in AEA may contribute to the improved cardiometabolic phenotype
induced by weight loss.
Introduction
The endocannabinoid (EC) system is a key player in
lipid and glucose metabolism and in regulation of energy
balance1. It consists of the cannabinoid receptors type 1
(CB1R) and type 2 (CB2R), their ligands, the endo-
cannabinoids (ECs), and the enzymes responsible for
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synthesis and degradation of ECs. The two most well-
studied ECs, anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), belong to the class of N-
acylethanolamines and monoacylglycerols, respectively.
The ECs are phospholipid-derived lipids that can be
produced by any cell type and organ and act mainly as
paracrine mediators. Binding of ECs to the cannabinoid
receptors results in various metabolic effects, including
increased food intake, enhanced lipogenesis and reduced
energy expenditure2,3. This is supported by several studies
reporting strong associations between high plasma EC
levels and triglycerides (TG), intra-abdominal obesity and
insulin resistance in obese and type 2 diabetes (T2D)
patients4–7. Furthermore, overactivity of the EC system
can promote beta cell failure through activation of the
Nlrp3-ASC inﬂammasome in inﬁltrating macrophages8.
Thus, elevated levels of ECs can contribute to relative
insulin deﬁciency and to accumulation of visceral adipose
tissue (VAT) and obesity, and as such may have a causal
role in the pathophysiology of T2D and CVD3.
The prevalence of T2D, which is associated with the
Western obesogenic lifestyle, is increasing9. T2D patients
have a two-fold increased risk to develop cardiovascular
disease (CVD), their major cause of death10. Moreover,
the 7-year incidence rate of myocardial infarction (MI)
following a previous MI is increased more than two-fold
in T2D patients compared to non-diabetic subjects11.
Many risk factors play a role in the development of car-
diovascular complications, and a major role is attributed
to ectopic lipid deposition. Ectopic lipid deposition sti-
mulates inﬂammation and causes insulin resistance,
probably as a consequence of accumulation of toxic
metabolites including diacylglycerol and ceramides that
interfere with the insulin signaling process12. For example,
lipid accumulation can occur in myocardial tissue and in
the pericardial fat depot, which is associated with
impaired myocardial function and increased risk and
degree of coronary atherosclerosis13–16.
Many studies have targeted the EC system to improve
metabolic health. Blockade of the CB1R with rimonabant
caused weight loss and improved lipid metabolism in
obese animal models and humans, but had unacceptable
psychiatric side effects17–20. Alternatively, EC levels can be
reduced by dietary interventions. For example, krill oil,
which has a high polyunsaturated fatty acid (PUFA)
content, reduces plasma 2-AG levels in obese humans,
probably by reducing the availability of EC biosynthetic
precursors21. Also, dietary long-chain PUFA reduces
ectopic fat deposition in liver and heart and susceptibility
for inﬂammation in Zucker rats22, 23, supporting a con-
nection between the EC system and ectopic lipid
deposition. Studies in humans assessing the effect of
weight loss on plasma EC levels show variable results:
while some studies showed a decrease in EC levels6, 24,
other studies showed no effect25, 26. The effect of more
pronounced weight loss by intensive caloric restriction on
plasma EC levels is as yet unknown.
Previously our group showed that prolonged caloric
restriction decreases ectopic fat deposition and improves
myocardial function in obese T2D patients without
CAD27. However, the effects of this intervention in T2D
patients with established CAD are still unknown. There-
fore, our aim was to investigate the effect of caloric
restriction on plasma EC levels, ectopic lipid accumula-
tion and cardiovascular function in obese patients with
T2D and established CAD.
Methods
Subjects
Obese (BMI> 25 kg/m²) T2D patients with documented
coronary artery disease (CAD) were recruited via adver-
tisements and from the outpatient clinic of the Leiden
University Medical Center (LUMC), Leiden, the Nether-
lands. Established atherosclerosis or CAD were deﬁned as
a history of MI and/or percutaneous coronary interven-
tion and/or a> 50% stenosis in a coronary artery as
documented by computed tomography angiography.
Exclusion criteria were hepatic disease, glomerular ﬁltra-
tion rate <60mL/min, congenital heart disease and gen-
eral contraindications to magnetic resonance (MR)
scanning. Subjects underwent a medical screening
including their medical history, physical examination, and
blood chemistry tests. The study was approved by the
local ethics committee and performed in accordance with
the principles of the revised Declaration of Helsinki.
Written informed consent was obtained from all subjects
before participation. The study was registered in the
Dutch Trial Register (NTR-2897).
Study design
The study was conducted at the LUMC, Leiden, the
Netherlands. Patients were studied on two occasions: at
baseline and after a 16-week dietary intervention period,
during which a VLCD was prescribed. In order to assess
the variability in study parameters without dietary inter-
vention, 13 of the 27 patients were also studied 16 weeks
prior to the start of the VLCD. Patients were instructed
not to alter lifestyle habits during the study.
The VLCD consisted of Prodimed products (Prodimed®
Benelux BV, Valkenswaard, the Netherlands), which
are low in calories and have a relatively high protein
content of 67% and a low fat content of 5%. All patients
started with total meal replacement: 4–6 sachets a day
(400–600 kcal/day) including a warm meal of Prodimed
for three weeks, supplemented with a limited choice of
vegetables. After these three weeks caloric intake was
increased, by replacing a Prodimed at dinner time by meat
or ﬁsh. Afterwards, when an additional 3% weight loss was
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achieved, the caloric intake was further expanded
with one Prodimed being replaced with a normal
meal. One week before the last study day, the diet
was expanded, with a normal breakfast to achieve a
caloric intake of 1000 kcal/day. Use of sulphonyl urea
derivatives was discontinued the day the VLCD started
and insulin therapy was adjusted according to glucose
levels. Patients on insulin treatment were asked to mea-
sure their blood glucose levels 4 times a day throughout
the study.
During the intervention period, patients visited the
outpatient clinic weekly, and blood pressure and body
weight were measured. Blood was drawn monthly to
assess safety parameters. At each study day, anthropo-
metric measurements, blood sampling and MR imaging
and spectroscopy were performed after ≥5 h of fasting.
Blood was centrifuged at 4 °C and EDTA plasma and
serum were stored at −80 °C until analyzses.
Biochemical assays
Serum concentrations of glucose, total cholesterol,
HDL-cholesterol and TG were measured on a Modular
P800 analyzer (Roche Diagnostics, Mannheim, Germany),
NEFA were measured using a commercial kit (Wako
Chemicals, Neuss, Germany), and insulin on an Immulite
2500 analyzer (Siemens, Breda, the Netherlands). LDL-
cholesterol was calculated according to Friedewald’s for-
mula28. HbA1c was measured on an HPLC system (Roche
Diagnostics, Mannheim, Germany). High-sensitivity CRP
(hs-CRP) levels were assessed using precoated 96-well
multisport plates from Meso Scale Discovery (Gaithers-
burg, Maryland, USA). Concentrations of ALT and AST
were measured with the Cobas Integra 800 analyzer
(Roche Diagnostics, Mannheim, Germany). Plasma levels
of several lipid species including ECs were quantiﬁed
using liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS) as described previously29.
MR spectroscopy and imaging
MR measurements were performed at a 1.5-Tesla MR-
scanner (Gyroscan ACS-NT15; Philips Medical Systems,
Best, the Netherlands).
Adipose tissue depots
The volume of pericardial fat, consisting of both epi-
cardial and paracardial fat, was derived from fat-selective
imaging using spectral presaturation with inversion
recovery, as described before30. Abdominal VAT
and subcutaneous adipose tissue (SAT) volumes
were quantiﬁed at the level of the ﬁfth lumbar vertebra,
using a turbo spin echo imaging sequence, as described
before15. Volumes of VAT and SAT were quantiﬁed using
MASS.
MR spectroscopy
Proton MR spectroscopy (1H-MRS) was performed to
quantify myocardial and hepatic TG content. Details on
acquisition and post processing were described pre-
viously31, 32. For the liver, voxel sites were matched at all
study occasions.
Delayed enhancement
Delayed enhancement MRI for detection of myocardial
scar was performed 15min after injection of gadetorate
meglumine (0.3 mL/kg, Dotarem; Guerbet, Bloomington,
USA) as described33.
Left ventricular dimensions and function
The heart was imaged in short-axis orientation to assess
systolic function, as previously described34. Left ven-
tricular (LV) end-diastolic and end-systolic contours were
drawn, using in-house developed validated MASS soft-
ware (LUMC, Leiden, the Netherlands). LV end-diastolic
volume, end-systolic volume, ejection fraction, mass,
cardiac output and stroke volume were calculated. Several
function parameters were indexed to body surface area.
LV mass was divided by LV end-diastolic volume to
obtain the LV mass/LV end-diastolic volume ratio, also
known as concentricity. LV diastolic function was studied
from transmitral ﬂow rate graphs, assessed from 3D
three-directional velocity encoded MRI with retrospective
valve tracking as previously described35. From the trans-
mitral ﬂow rate graphs, the following LV diastolic func-
tion parameters were determined using MASS software:
maximal ﬂow velocities and peak ﬁlling rate in early dia-
stole and at diastolic atrial contraction. The ratio between
peak ﬁlling at early diastole and diastolic atrial contraction
was calculated. In addition, the downslope after early peak
ﬁlling rate (deceleration) and the ratio between maximal
ﬂow velocity during early diastole and the through-plane
velocity assessed in the myocardial wall, which is the
estimate of the LV ﬁlling pressure, were assessed36, 37.
Pulse wave velocity
To evaluate aortic stiffness, aortic pulse wave velocity
(PWV) was determined, using in-house developed and
validated Matlab software (LUMC, Leiden, The Nether-
lands) as previously described38. A scout view of the aorta
was obtained. Subsequently, two time-resolved velocity-
encoded acquisitions perpendicular to the ascending aorta
at the level of the pulmonary trunk and at the level of the
aortic bifurcation were assessed, resulting in through-
plane ﬂow measurements. PWV was calculated with the
formula: Δx/Δt. Δx is the length of the aorta between two
measurement sites and Δt is the time delay between the
arrivals of the foot of the pulse wave at the respective
measurements site. The distance between the measure-
ment sites was determined manually with MASS. MASS
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and FLOW (LUMC, Leiden, the Netherlands) were used
for data analysis.
Statistical analysis
Data are presented as mean± SD or as median (inter-
quartile range (IQR)) when not normally distributed.
Based on the previous 16 week VLCD study we performed
in obese patients with T2DM without cardiovascular
complications, we performed a sample size calculation27.
A p value< 0.05 was considered statistically signiﬁcant.
Changes within participants were assessed using paired
sample t-tests or Wilcoxon signed-rank test when
appropriate. Linear regression analysis computed by
Pearson’s correlation was performed to identify correla-
tions between plasma EC levels and various metabolic
parameters. Statistical analyzes were performed with SPSS
for Windows, version 23.0 (SPSS Inc., Chicago, USA).
Results
Clinical characteristics
While 32 patients were initially included to receive
VLCD intervention, two patients left the study due to
intolerance to the diet, one patient left because of wor-
sening of Ménière’s disease, and two patients were
excluded due to non-adherence to the diet. Of the 27
participants who completed the study, results are shown
in Table 1. Individuals were on average 62.2 ± 6.0 year-
s old, had a body weight of 98.5 ± 16.0 kg, a BMI of 32.2
± 4.7 kg/m2, and most of them were male (82%).
VLCD induced an average weight loss of 16.5 ± 5.5 kg (p
< 0.001), and BMI decreased on average with 5.4 ± 1.7
kg/m2 (p < 0.001). VLCD improved glycemic control,
as reﬂected by decreased fasting plasma glucose levels
and decreased HbA1c levels. VLCD decreased ALT,
decreased total cholesterol and TG, and increased
HDL-cholesterol, without changing NEFA. In addition,
VLCD reduced systolic and diastolic blood pressures and
heart rate.
Sixteen of these 27 patients had previously experienced
a MI, 24 underwent percutaneous coronary intervention
and three patients had a coronary artery bypass grafting.
One patient had >50% occlusion of the coronary arteries
on computed tomography angiography without a sub-
sequent intervention. There were no differences in age,
duration of T2D or anthropometric measurements
between patients with and without a MI in medical his-
tory. At baseline 12 patients used insulin and all patients
were on oral antihyperglycemic drugs. During the VLCD,
insulin treatment was discontinued in 3 patients and in
three patients all glucose lowering drugs could be dis-
continued. As shown in Supplementary Table 1, clinical
and metabolic parameters of the subgroup of 13 patients
that was studied 16 weeks prior to the start of the VLCD
did not change during this period. Also, MR parameters
showed no signiﬁcant variability before start of VLCD, as
shown in Supplementary Table 2.
Endocannabinoid levels
The effects of the VLCD on plasma levels of the various
ECs and lipid species are summarized in Table 2. VLCD
decreased virtually all ECs from the group of N-acy-
lethanolamines, without decreasing any ECs belonging to
the group of monoacylglycerols. With respect to the most
well studied CBR ligands, VLCD decreased plasma AEA
levels (−13%; p= 0.024), without signiﬁcantly decreasing
plasma 2-AG levels (Table 2; Fig. 1). At baseline, plasma
2-AG levels did not correlate with either BMI, VAT and
SAT volume (not shown). Interestingly, baseline plasma
AEA levels correlated positively with BMI (R2= 0.21, p=
0.017) and, while plasma AEA levels did not correlate with
VAT volume, they strongly correlated positively with SAT
volume (R2= 0.44, p< 0.001) (Fig. 2). Plasma levels of 2-
AG, but not AEA, correlated with TG levels (R2= 0.41, p
< 0.001). Changes in plasma AEA and 2-AG levels as
induced by the VLCD did not correlate with changes in
adipose tissue volumes and parameters of cardiac function
(Supplement Table 3).
Adipose tissue distribution
VLCD reduced VAT volume (−52%, p< 0.001) and
SAT volume (−35%, p< 0.001) (Fig. 3). Furthermore,
VLCD substantially decreased hepatic TG content (−86%,
p< 0.001). VLCD also reduced epicardial fat volume
(−15%, p< 0.001) and paracardial fat volume (−28%, p<
0.001). Delayed enhancement MRI revealed a septal MI in
ﬁve patients, which prohibited myocardial TG measure-
ments in these patients. Myocardial TG in the other
patients decreased after VLCD (−33%, p< 0.001). There
were no differences in myocardial TG in patients with or
without MI.
Cardiovascular parameters
The changes in cardiac dimensions and function before
and after 16 weeks caloric restriction are shown in
Table 3. While VLCD did not inﬂuence diastolic function,
as the ratio of peak ﬁlling at early diastole and diastolic
atrial contraction, the downslope after early peak ﬁlling
rate, and the estimated ﬁlling pressure remained
unchanged, VLCD did decrease LV mass and improved
systolic cardiac function, as evidenced by an increased
ejection fraction. VLCD also decreased cardiac output and
increased end-diastolic volume and stroke volume. Fur-
thermore, VLCD decreased aortic PWV from 7.9± 1.9 m/
s at baseline to 7.2± 1.1 m/s (p= 0.016) after VLCD.
Discussion
In this study, we observed that a VLCD for 16 weeks
decreased plasma levels of the CBR agonist AEA and
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other ECs we measured of the class of N-acylethanola-
mines in obese patients with T2D and established cor-
onary atherosclerosis. Furthermore, VLCD resulted in
reductions in SAT and VAT volume, reduced ectopic
lipid accumulation, and improved cardiovascular
function.
We show for the ﬁrst time that vigorous caloric
restriction with substantial weight loss and decrease of all
adipose tissue depots can reduce AEA and other N-acy-
lethanolamines in patients with T2D. In contrast, VLCD
did not affect plasma levels of the EC 2-AG and other
monoacylglycerols. Two previous studies have investi-
gated the effect of small reductions of body weight on EC
levels, both showing no effect25, 26. Di Marzo et al.6
reported decreased plasma levels of AEA and 2-AG after a
one year lifestyle modiﬁcation program including healthy
eating and physical activity in obese men without T2D.
Furthermore, the decrease in 2-AG in that study corre-
lated positively with a decrease in VAT volume. In our
study, however, effects of VLCD on 2-AG and correla-
tions between changes in 2-AG and VAT were not
observed, due to reasons unknown to us. Furthermore, in
our study, AEA levels at baseline correlated strongly with
SAT volume, but not with VAT volume, which to our
knowledge was not described before.
It is interesting to speculate on the mechanism behind
our observation that VLCD reduces AEA and other N-
acylethanolamines. Potentially, the VLCD can have
reduced the availability of biosynthetic precursors,
thereby explaining decreased levels of N-acylethanola-
mines. Furthermore, the reduced volume of adipose tis-
sue, being a source of EC production, could explain
reduced AEA levels. Also, we cannot exclude that
Table 1 Clinical and metabolic characteristics of obese type 2 diabetes patients with documented coronary artery
disease before and after very low calorie diet
Before VLCD After VLCD p value
Clinical characteristics
Age (years) 62.2 ± 6.0
Males, n (%) 22 (82%)
T2D duration (years) 11.0 ± 8.5
Patients on insulin, n (%) 12 (44%) 9 (33%)
Insulin dose (units/day) 79 ± 36 16 ± 12
Body weight (kg) 98.5 ± 16.0 82.0 ± 14.0 <0.001
BMI (kg/m2) 32.2 ± 4.7 26.8 ± 4.1 <0.001
Waist circumference (cm) 111 ± 12 93 ± 11 <0.001
Systolic blood pressure (mmHg) 146 ± 14 129 ± 12 <0.001
Diastolic blood pressure (mmHg) 83 ± 10 75 ± 9 0.002
Heart rate (beats/min) 68 ± 12 60 ± 8 0.002
Metabolic characteristics
Glucose (mmol/L) 7.4 ± 1.7 6.3 ± 1.2 0.002
HbA1c (%) 6.9 ± 0.9 5.8 ± 0.5 <0.001
HbA1c (mmol/mol) 51 ± 10 40 ± 6 <0.001
Triglycerides (mmol/L) 1.80 ± 0.89 1.17 ± 0.43 <0.001
Total cholesterol (mmol/L) 4.18 ± 0.86 3.82 ± 0.67 0.018
HDL-cholesterol (mmol/L) 1.18 ± 0.28 1.32 ± 0.34 0.001
LDL-cholesterol (mmol/L) 2.18 ± 0.71 1.97 ± 0.60 0.088
NEFA (mmol/L) 0.61 ± 0.25 0.59 ± 0.29 0.836
ALT (IU/L) 30 ± 10 24 ± 11 0.024
AST (IU/L) 25 ± 7 22 ± 7 0.057
hs-CRP (mg/L) 1.7 (4.5) 1.1 (3.0) 0.107
Data are means ± SD or median (interquartile range), n = 27. p value before vs. after diet based on a paired sample t-test or Wilcoxon signed-rank test
ALT alanine transaminase, AST aspartate transaminase, hs-CRP high-sensitivity C-reactive protein, IU International unit
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decrease or discontinuation of use of insulin injections
and glucose lowering drugs has affected plasma levels of
the measured lipid species. However, in our opinion, it is
likely that VLCD inﬂuenced the activity or expression of
enzymes responsible for degradation of ECs. After all, it is
known that in adipocytes from normoglycemic non-obese
subjects the expression of fatty acid amide hydrolase
(FAAH), the enzyme responsible for degradation of
mainly AEA and other N-acylethanolamines, is increased
upon stimulation with insulin39. Furthermore, it has been
shown in vivo that insulin functions as a negative reg-
ulator of AEA levels in non-diabetic subjects, but not in
insulin-resistant individuals, probably due to lack of sti-
mulation of expression of FAAH in adipocytes40. It is thus
conceivable that the decrease in adipose tissue volume as
induced by VLCD in our study improves insulin sensi-
tivity of adipocytes thereby increasing FAAH expression
and decreasing plasma levels of AEA and other N-acy-
lethanolamines. This hypothesis is supported by our
unpublished data showing a higher gene expression of
FAAH in SAT in normal glucose tolerant subjects than in
subjects with T2D (Van Eyk, unpublished). The fact that
FAAH degrades N-acylethanolamines but not mono-
acylglycerols41, may explain why VLCD does not reduce
monoacylglycerols including 2-AG.
We also detected a decreased LV mass and heart rate
after VLCD, which can be considered beneﬁcial, since
both are recognized as important predictors for cardio-
vascular disease42, 43. Furthermore, the ejection fraction
increased after VLCD, which was not observed in other
studies with a similar approach27, 44. The improvement of
ejection fraction in the current study is clinically very
relevant, since LV ejection fraction is an important pre-
dictor of mortality in T2D patients45. Moreover, we show
that parameters of LV function also improve in patients
with complicated T2D, corroborating previous observa-
tions in uncomplicated T2D27. Other investigators
observed an improved LV systolic function after weight
loss, though based on other parameters than an improved
ejection fraction46, 47. However, those studies differed
considerably from our study, as not all patients had T2D
and/or CAD. Although the estimate of the LV ﬁlling
pressure, did not change after the diet, the increased end-
diastolic volume at similar estimates of LV ﬁlling pressure
Table 2 Plasma levels of lipid species before and after very low calorie diet
Before VLCD After VLCD p value
N-acylethanolamines (pmol/mL)
AEA 0.94 ± 0.41 0.82 ± 0.30 0.024
PEA 7.57 ± 2.03 6.26 ± 1.28 <0.001
SEA 6.36 ± 1.79 4.88 ± 0.87 <0.001
POEA 0.55 ± 0.47 0.34 ± 0.24 0.003
OEA 5.13 ± 1.57 4.74 ± 1.17 0.091
LEA 2.52 ± 0.64 2.13 ± 0.38 0.001
Alpha-LEA 0.19 ± 0.06 0.15 ± 0.03 0.003
DGLEA 0.16 ± 0.08 0.12 ± 0.04 <0.001
PDEA 0.09 ± 0.03 0.08 ± 0.02 0.105
EPEA 0.60 ± 0.37 0.37 ± 0.24 0.001
DEA 0.28 ± 0.08 0.25 ± 0.07 0.009
DHEA 5.51 ± 2.16 4.21 ± 2.04 <0.001
Monoacylglycerols (pmol/mL)
2-AG 2.63 ± 1.25 2.42 ± 0.82 0.355
1-OG 425 ± 35 423 ± 38 0.828
2-OG 75 ± 30 68 ± 18 0.189
1-LG 79 ± 19 76 ± 14 0.378
2-LG 24 ± 11 21 ± 8 0.279
Data are mean ± SD, n = 27. p value before vs. after VLCD based on a paired sample t-test
1-LG 1-linoleoyl glycerol, 1-OG 1-oleoyl glycerol, 2-AG 2-arachidonoyl glycerol, 2-LG 2-linoleoyl glycerol, 2-OG 2-oleoyl glycerol, AEA anandamide, Alpha-LEA N-α-
linolenylethanolamide, DEA N-docosatetraenoylethanolamide, DGLEA dihomo-γ-linolenoyl ethanolamide, DHEA N-docosahexaenoylethanolamide, EPEA eicosapen-
taenoyl ethanolamide, LEA: N-linoleoylethanolamide, OEA N-oleoylethanolamide, PDEA N-pentadecanoylethanolamide, PEA N-palmitoylethanolamide, POEA N-
palmitoleoylethanolamide, SEA N-stearoylethanolamide
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suggests an improved LV compliance48. Diastolic function
did not change after VLCD in contrast to previous studies
in uncomplicated T2D that found signiﬁcant improve-
ments in the ratio between peak ﬁlling at early diastole
and diastolic atrial contraction after prolonged caloric
restriction27. Our study showed a decrease in PWV, a
surrogate marker for arterial stiffness and a powerful
independent predictor of cardiovascular events, indicating
a less stiff aorta49. No prior studies have been published
on the effects of dietary intervention on PWV in com-
plicated T2D.
Because ECs have various metabolic effects, including
increase of food intake and lipogenesis and reduction of
energy expenditure, the reduction of AEA may have
contributed to the metabolic improvements and may have
ampliﬁed the reduction of adipose tissue volume we
observed. This way, the positive correlation between
baseline plasma AEA levels and SAT volume suggests that
decreased AEA levels might have contributed to reduced
fat accumulation in SAT, although we were unable to
detect a positive correlation between the changes of the
variables, possibly related to insufﬁcient power. Further-
more, Batetta et al.23 reported reductions of EC levels
after dietary intervention with long-chain PUFA in Zucker
rats, accompanied with reductions of ectopic lipid
deposition in liver and heart. Therefore, the reduction in
AEA may have contributed to the decrease in myocardial
TG content, which is known to be associated with
impaired myocardial function15. Also, it was recently
shown that increased EC levels are associated with
impaired coronary circulatory function and even more
importantly, that gastric bypass-induced weight loss
reduced EC levels and beneﬁcially affected coronary cir-
culatory function24, 50, which suggests that the decrease in
AEA might also have contributed to the improved cardiac
function we observed.
The associative nature of our study does not allow to
establish a causal relationship between the reduction in
EC levels and cardiometabolic phenotype, including
weight loss, ectopic lipid deposition, or measures of
Fig. 1 Plasma levels of AEA and 2-AG before and after VLCD. Change in AEA (a) and 2-AG (b). *p < 0.05 vs. before VLCD, n = 27
Fig. 2 Correlations of AEA with BMI and adipose tissue volume. AEA plasma levels in relation to BMI (a), VAT volume (b), and SAT volume (c) as
measured at baseline, n = 27
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cardiac function. However, considering the remarkable
beneﬁcial effects of the CB1R inverse agonist rimonabant
on body weight and lipid levels19, 20, it is likely that the EC
system is an important player in metabolism. This makes
a role for the EC system in the metabolic improvements
we observed plausible. Future studies speciﬁcally targeting
the EC system with dietary or pharmacological interven-
tions can provide further knowledge and help entangle the
role of ECs in the development of disease. Also, studying
short term effects of caloric restriction, before weight loss
has occurred, on EC levels could provide more informa-
tion about the mechanism. Importantly, we show that
prolonged caloric restriction, regardless of the role of ECs,
improves cardiac function. Direct and indirect beneﬁcial
effects of caloric restriction and weight loss may have
contributed to improved cardiac function, such as
decreased blood pressure, improved glycemic control and
improved PWV.
A strength of this study is that it is the ﬁrst to investi-
gate the effects of prolonged caloric restriction on EC
levels in relation to cardiovascular function and ectopic
fat distribution in overweight T2D patients with
established CAD. Furthermore in a subgroup, it was
established that study parameters did not change without
dietary intervention. A limitation to this study is that
patients followed a diet with very low caloric content and
speciﬁc composition. It thus remains to be determined
whether similar effects would be obtained by other
interventions that induce similar weight loss. Another
limitation is that due to practical issues patients were
studied after ≥5 h of fasting, which may be too short for
some participants to reach baseline metabolic state.
However, to reliably compare intra-individual data, we
studied each patient at subsequent visits after the same
fasting time. Finally, we investigated circulating ECs only,
because EC concentrations, receptor expression and
enzymes that play a role in synthesis and degradation of
ECs within metabolic tissues could for obvious reasons
not be investigated.
In conclusion, we showed that caloric restriction
superposed on optimal pharmacological therapy for glu-
coregulation improves cardiovascular function in patients
with advanced T2D. Since T2D is associated with
increased cardiovascular mortality, the results of this
Fig. 3 Volumes of various adipose tissue compartments before and after VLCD. Change in SAT volume (a), VAT volume (b), hepatic TG content
(c), epicardial adipose tissue volume (d), paracardial adipose tissue (e) and myocardial TG content (n = 22) (f). Results are expressed as mean ± SD. ***
p < 0.001 vs. before VLCD, n = 27, except for F, n = 22
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study are highly clinically relevant. Considering the role of
ECs in metabolism, we anticipate that the reduction in
AEA may contribute to the improved metabolic pheno-
type induced by weight loss. However, mechanistic studies
will have to be performed to establish the causal role of
dysregulation of the EC system in ectopic lipid deposition
and CAD.
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